Skip to main content

Table 3 Structural disease progression in patients with early RA who received DMARDs and the entire ESPOIR cohort.

From: Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort

  SD-treated patients All ESPOIR patients
All patients (number = 370) (number = 736a)
- ΔvSHS total 1.6 ± 5.5 (0) 0.96 ± 4.4 (0)
- ΔvSHS erosion 1.5 ± 4.7 (0) 0.96 ± 3.8 (0)
- ΔvSHS narrowing 0.2 ± 1.8 (0) 0.01 ± 1.81 (0)
Patients with structural progression b (number = 126, 34.1%) (number = 187, 25.4%)
- ΔvSHS total 5.4 ± 7.0 [54] 5.0 ± 6.3 [54]
- ΔvSHS ≥ 5 points (RRP) 41 (11.1%) 58 (7.9%)
  1. Data are mean ± SD (median) or number (%).aX-ray data were available for only 736 patients; bStructural progression was defined as ΔvSHS ≥ 1 point (that is, the smallest detectable difference). DMARD, disease-modifying anti-rheumatic drugs; RRP, rapid radiographic progression; SD, synthetic DMARD; ΔvSHS, change in van der Heijde-modified Sharp score.